Active	Status	Sponsor type	Region	Phase	Filter
1 Active 6 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ornstein, Mark
RETHINK-1, NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease	Active, not recruiting	3	750	Canada, US, RoW	Simufilam, PTI-125, Placebo	Cassava Sciences, Inc., Premier Research Group plc	Alzheimer Disease	10/24	10/24